株式会社京都創薬研究所

Kyoto, JP · 2 known investors

Kyoto Drug develops novel therapeutic drugs for rare and difficult-to-treat ocular diseases including retinal artery occlusion and retinitis pigmentosa, using a new small-molecule compound (KUS agent) based on research from Kyoto University.

BiotechMedical Devices